Phase 2 of Growth Hormone for Treatment of Albright Hereditary Osteodystrophy

生长激素治疗奥尔布赖特遗传性骨营养不良症的第二阶段

基本信息

项目摘要

DESCRIPTION (provided by applicant): Albright hereditary osteodystrophy (AHO) is a rare genetic disorder caused by heterozygous inactivating mutations in the gene encoding the a chain of stimulatory gene proteins (Gs). Among other abnormalities, it is associated with short stature and obesity. Because of tissue-specific imprinting, patients with GNAS mutations on maternally inherited alleles are resistant to multiple G protein-coupled hormones, a variant termed pseudohypoparathyroidism type 1a (PHP1a). Patients who inherit mutations from the paternal allele have a similar phenotype but without hormonal resistance, termed pseudopseudohypo- parathyroidism (PPHP). The investigators hypothesized that PHP1a patients are resistant to growth hormone releasing hormone and found that approximately two-thirds are growth hormone (GH) deficient. GH therapy has led to increased growth velocities, taller adult heights, decreased BMI and adiposity, and improvements in lipids, bone density, sense of well-being, and self-esteem without any significant side effects from GH use. However, GH deficiency is not the only cause of the short stature in PHP1a. Premature fusion of the epiphyses reflected in advanced bone ages is also a cause and occurs in patients with PHP1a who are GH-sufficient as well as in patients with PPHP. In vitro and mouse studies have implicated that haploinsufficiency of G protein in chondrocytes in PHP1a and PPHP causes premature chondrocyte differentiation which could be the etiology. Based on the promising results with the GH trial in GH- deficient PHP1a patients, the hypothesis is that GH may also be of value in children with PHP1a who are GH-sufficient as well as in children with PPHP by accelerating growth velocity maximally prior to the cessation of growth secondary to early bone fusion. This study will examine the effects of GH on growth velocity in prepubertal GH-sufficient children with PHP1a and PPHP. Preliminary data for safety and dosing of GH, as well as quality of life effects will be gathered. If the results are promising, these children will be followed to final height after completion of this proposed initial investigation. This ultimately could lead to a new FDA-approved indication for GH use in all children with AHO, thus eliminating the need for GH testing for these children. The overall goal is to improve the quality of life in these patients.
描述(由申请人提供): 奥尔布赖特遗传性骨营养不良(Albright hereditary osteodystrophy,AHO)是一种罕见的遗传性疾病,由编码刺激基因蛋白(Gs)的α链基因的杂合失活突变引起。 在其他异常中,它与身材矮小和肥胖有关。 由于组织特异性印记,母系遗传等位基因上存在GNAS突变的患者对多种G蛋白偶联激素具有耐药性,这种变体称为1a型假性甲状旁腺功能减退症(PHP1a)。 从父系等位基因遗传突变的患者具有相似的表型,但没有激素抵抗,称为假甲状旁腺功能低下症(PPHP)。 研究人员假设PHP1a患者对生长激素释放激素有抵抗力,并发现大约三分之二的人缺乏生长激素(GH)。 生长激素治疗导致生长速度增加,成人身高更高,BMI和肥胖降低,血脂,骨密度,幸福感和自尊改善,而没有任何显着的副作用。 然而,GH缺乏不是PHP1a矮小的唯一原因。 骨龄提前反映的骨骺过早融合也是一个原因,发生在GH充足的PHP1a患者和PPHP患者中。 体外和小鼠研究表明,PHP1a和PPHP中软骨细胞中G蛋白的单倍不足导致软骨细胞过早分化,这可能是病因。 基于GH缺乏PHP1a患者中GH试验的良好结果,假设GH在GH充足的PHP1a儿童以及PPHP儿童中也可能有价值,因为在继发于早期骨融合的生长停止之前,GH可最大限度地加速生长速度。 本研究将探讨生长激素对青春期前生长激素不足的PHP1a和PPHP儿童生长速度的影响。 将收集GH安全性和剂量以及生活质量影响的初步数据。 如果结果令人满意,则在完成拟定的初步研究后,将对这些儿童进行随访,直至最终身高。 这最终可能导致FDA批准的所有AHO儿童使用GH的新适应症,从而消除这些儿童对GH检测的需要。 总体目标是改善这些患者的生活质量。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EMILY L GERMAIN-LEE其他文献

EMILY L GERMAIN-LEE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EMILY L GERMAIN-LEE', 18)}}的其他基金

Elucidating extragonadal functions of follicle stimulating hormone using genetic approaches in mice
利用小鼠遗传方法阐明促卵泡激素的性腺外功能
  • 批准号:
    10685473
  • 财政年份:
    2022
  • 资助金额:
    $ 13.9万
  • 项目类别:
Extracellular regulation of bone mass by transforming growth factor-ß-related ligands and their binding proteins
通过转化生长因子相关配体及其结合蛋白对骨量进行细胞外调节
  • 批准号:
    10537833
  • 财政年份:
    2022
  • 资助金额:
    $ 13.9万
  • 项目类别:
Extracellular regulation of bone mass by transforming growth factor-ß-related ligands and their binding proteins
通过转化生长因子相关配体及其结合蛋白对骨量进行细胞外调节
  • 批准号:
    10669763
  • 财政年份:
    2022
  • 资助金额:
    $ 13.9万
  • 项目类别:
Elucidating extragonadal functions of follicle stimulating hormone using genetic approaches in mice
利用小鼠遗传方法阐明促卵泡激素的性腺外功能
  • 批准号:
    10534492
  • 财政年份:
    2022
  • 资助金额:
    $ 13.9万
  • 项目类别:
The role of G protein-coupled signaling in neurocognitive and psychosocial abnormalities
G 蛋白偶联信号在神经认知和心理社会异常中的作用
  • 批准号:
    9035448
  • 财政年份:
    2016
  • 资助金额:
    $ 13.9万
  • 项目类别:
The role of G protein-coupled signaling in neurocognitive and psychosocialabnormalities
G 蛋白偶联信号在神经认知和心理社会异常中的作用
  • 批准号:
    9331967
  • 财政年份:
    2016
  • 资助金额:
    $ 13.9万
  • 项目类别:
The role of G protein-coupled signaling in neurocognitive and psychosocialabnormalities
G 蛋白偶联信号在神经认知和心理社会异常中的作用
  • 批准号:
    9234576
  • 财政年份:
    2016
  • 资助金额:
    $ 13.9万
  • 项目类别:
Phase 2 of Growth Hormone for Treatment of Albright Hereditary Osteodystrophy
生长激素治疗奥尔布赖特遗传性骨营养不良症的第二阶段
  • 批准号:
    8320750
  • 财政年份:
    2010
  • 资助金额:
    $ 13.9万
  • 项目类别:
Phase 2 of Growth Hormone for Treatment of Albright Hereditary Osteodystrophy
生长激素治疗奥尔布赖特遗传性骨营养不良症的第二阶段
  • 批准号:
    8032580
  • 财政年份:
    2010
  • 资助金额:
    $ 13.9万
  • 项目类别:
STUDIES OF HORMONE ACTION IN PATIENTS WITH ALTERED G PROTEIN FUNCTION
G 蛋白功能改变患者的激素作用研究
  • 批准号:
    7604526
  • 财政年份:
    2006
  • 资助金额:
    $ 13.9万
  • 项目类别:

相似国自然基金

基于FP-Growth关联分析算法的重症患者抗菌药物精准决策模型的构建和实证研究
  • 批准号:
    2024Y9049
  • 批准年份:
    2024
  • 资助金额:
    100.0 万元
  • 项目类别:
    省市级项目
Research on the Rapid Growth Mechanism of KDP Crystal
  • 批准号:
    10774081
  • 批准年份:
    2007
  • 资助金额:
    45.0 万元
  • 项目类别:
    面上项目

相似海外基金

Elucidation of regulatory mechanisms of the growth hormone cytokinin and nitrogen dynamics in plant adaptation to nitrate fluctuation stress
阐明植物适应硝酸盐波动胁迫中生长激素细胞分裂素和氮动态的调节机制
  • 批准号:
    24K18138
  • 财政年份:
    2024
  • 资助金额:
    $ 13.9万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Growth hormone regulating chondrocyte metabolism for osteoarthritis development
生长激素调节软骨细胞代谢促进骨关节炎的发展
  • 批准号:
    10730575
  • 财政年份:
    2023
  • 资助金额:
    $ 13.9万
  • 项目类别:
Developing helical peptide antagonists of the growth hormone receptor
开发生长激素受体的螺旋肽拮抗剂
  • 批准号:
    10648820
  • 财政年份:
    2023
  • 资助金额:
    $ 13.9万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 13.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Central Mediation of Growth Hormone Effects in Humans
人类生长激素效应的中枢调节
  • 批准号:
    10659801
  • 财政年份:
    2023
  • 资助金额:
    $ 13.9万
  • 项目类别:
CREUTZFELDT-JAKOB DISEASE SURVEILLANCE IN RECIPIENTS OF HUMAN GROWTH HORMONE
人类生长激素接受者的克雅氏病监测
  • 批准号:
    10973401
  • 财政年份:
    2023
  • 资助金额:
    $ 13.9万
  • 项目类别:
Metabolomic Investigation of the Impact of Growth Hormone on Nonalcoholic Fatty Liver Disease: Identification of Novel Biomarkers and Therapeutic Targets
生长激素对非酒精性脂肪肝影响的代谢组学研究:新型生物标志物和治疗靶点的鉴定
  • 批准号:
    10451082
  • 财政年份:
    2022
  • 资助金额:
    $ 13.9万
  • 项目类别:
Metabolomic Investigation of the Impact of Growth Hormone on Nonalcoholic Fatty Liver Disease: Identification of Novel Biomarkers and Therapeutic Targets
生长激素对非酒精性脂肪肝影响的代谢组学研究:新型生物标志物和治疗靶点的鉴定
  • 批准号:
    10608193
  • 财政年份:
    2022
  • 资助金额:
    $ 13.9万
  • 项目类别:
Growth differentiation factor-15 (GDF15) as a novel myocardial hormone in heart failure
生长分化因子 15 (GDF15) 作为一种新型心肌激素治疗心力衰竭
  • 批准号:
    10557842
  • 财政年份:
    2022
  • 资助金额:
    $ 13.9万
  • 项目类别:
Growth differentiation factor-15 (GDF15) as a novel myocardial hormone in heart failure
生长分化因子 15 (GDF15) 作为一种新型心肌激素治疗心力衰竭
  • 批准号:
    10335004
  • 财政年份:
    2022
  • 资助金额:
    $ 13.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了